Newsroom May 14, 2026 Affinia Therapeutics Presents AFTX-201 Data and UPBEAT© Clinical Trial Design for BAG3-Associated Dilated Cardiomyopathy, Alongside Advances in BBB-Penetrant AAV Capsids and Proprietary Manufacturing, at the 29th ASGCT 2026 Annual Meeting View More April 28, 2026 Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting View More April 6, 2026 Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM) View More March 4, 2026 Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) View More February 18, 2026 Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM) View More February 4, 2026 Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM) View More
